Australia markets closed

4D pharma plc (FRPRF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.2100+0.0100 (+0.83%)
At close: 2:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2000
Open1.2100
BidN/A x N/A
AskN/A x N/A
Day's range1.2100 - 1.2100
52-week range0.6800 - 2.3000
Volume100
Avg. volume27,236
Market cap223.059M
Beta (5Y monthly)2.82
PE ratio (TTM)N/A
EPS (TTM)-0.2670
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    4D pharma Announces $30 Million Credit Facility with Oxford Finance

    LEEDS, England, July 29, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the closing of a senior secured credit facility for up to $30m with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies.

  • Business Wire

    4D pharma Announces Passing of Chief Financial Officer John Beck

    LEEDS, England, July 26, 2021--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces with great sadness that John Beck, Chief Financial Officer of 4D pharma, has passed away.

  • Business Wire

    4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T

    LEEDS, England, July 06, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the publication of pre-clinical research relating to its second-generation immuno-oncology LBP MRx1299 improving the activity of CAR-T.